NIH R01 · 2025
Modulating Fibrinolysis Dynamics by Leveraging Multivalent Avidity to Control Enzyme Activity
PROJECT SUMMARY Blood clots kill more humans than any other single pathogenic cause. A new or recurrent diagnosis of venous thromboembolism (VTE), which encompasses both pulmonary embolism (PE) and deep vein thrombosis (DVT), affects >900,000 people each year in the US alone. Current PE standard of care includes the delivery of acute clot digesting enzymes such as recombinant tissue Plasminogen Activator (tPA), administered IV or by catheter. All currently FDA cleared clot digesting enzymes rely on activation of the patient’s endogenous plasminogen converting nearly all of it to active clot digesting plasmin. This widespread activation massively depletes plasmin regulatory proteins, causing…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.